Optimizing patient expectancy in the pharmacologic treatment of major depressive disorder

被引:0
|
作者
Zilcha-Mano, Sigal [1 ]
Brown, Patrick J. [2 ]
Roose, Steven P. [2 ]
Cappetta, Kiley [2 ]
Rutherford, Bret R. [2 ]
机构
[1] Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel
[2] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, New York, NY 10032 USA
关键词
expectancy; major depressive disorder; placebo effects; PLACEBO-RESPONSE; BETWEEN-PERSON; WITHIN-PERSON; METAANALYSIS; DESIGN; ALLIANCE; QUESTION; MODELS;
D O I
10.1017/S0033291718003343
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Patient expectancy is an important source of placebo effects in antidepressant clinical trials, but all prior studies measured expectancy prior to the initiation of medication treatment. Little is known about how expectancy changes during the course of treatment and how such changes influence clinical outcome. Consequently, we undertook the first analysis to date of in-treatment expectancy during antidepressant treatment to identify its clinical and demographic correlates, typical trajectories, and associations with treatment outcome. Methods Data were combined from two randomized controlled trials of antidepressant medication for major depressive disorder in which baseline and in-treatment expectancy assessments were available. Machine learning methods were used to identify pre-treatment clinical and demographic predictors of expectancy. Multilevel models were implemented to test the effects of expectancy on subsequent treatment outcome, disentangling within- and between-patient effects. Results Random forest analyses demonstrated that whereas more severe depressive symptoms predicted lower pre-treatment expectancy, in-treatment expectancy was unrelated to symptom severity. At each measurement point, increased in-treatment patient expectancy significantly predicted decreased depressive symptoms at the following measurement (B = -0.45, t = -3.04, p = 0.003). The greater the gap between expected treatment outcomes and actual depressive severity, the greater the subsequent symptom reductions were (B = 0.49, t = 2.33, p = 0.02). Conclusions Greater in-treatment patient expectancy is associated with greater subsequent depressive symptom reduction. These findings suggest that clinicians may benefit from monitoring and optimizing patient expectancy during antidepressant treatment. Expectancy may represent another treatment parameter, similar to medication compliance and side effects, to be regularly monitored during antidepressant clinical management.
引用
收藏
页码:2414 / 2420
页数:7
相关论文
共 50 条
  • [11] Amantadine: a treatment for major depressive disorder
    Ruiz-Chow, A.
    Ramirez-Bermudez, J.
    Alviso-de la Serna, L.
    Rios, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S352 - S352
  • [12] Vortioxetine for the treatment of major depressive disorder
    Tritschler, Laurent
    Felice, Daniela
    Colle, Romain
    Guilloux, Jean-Philippe
    Corruble, Emmanuelle
    Gardier, Alain Michel
    David, Denis Joseph
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (06) : 731 - 745
  • [13] Agomelatine Treatment of Major Depressive Disorder
    Dolder, Christian R.
    Nelson, Michael
    Snider, Morgan
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (12) : 1822 - 1831
  • [14] Desvenlafaxine in the treatment of major depressive disorder
    Lourenco, Maria Teresa C.
    Kennedy, Sidney H.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2009, 5 : 127 - 136
  • [15] Desvenlafaxine for the treatment of major depressive disorder
    Kornstein, Susan G.
    McIntyre, Roger S.
    Thase, Michael E.
    Boucher, Matthieu
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (10) : 1449 - 1463
  • [16] Vortioxetine in the treatment of major depressive disorder
    Baldwin, David S.
    Hanumanthaiah, Venkatesh Ballagere
    FUTURE NEUROLOGY, 2015, 10 (02) : 79 - 89
  • [17] Diagnosis and Treatment of Major Depressive Disorder
    Soleimani, Laili
    Lapidus, Kyle A. B.
    Iosifescu, Dan V.
    NEUROLOGIC CLINICS, 2011, 29 (01) : 177 - +
  • [18] Vilazodone for the Treatment of Major Depressive Disorder
    Iranikhah, Maryam
    Wensel, Terri M.
    Thomason, Angela R.
    PHARMACOTHERAPY, 2012, 32 (10): : 958 - 965
  • [19] Treatment of major depressive disorder in epilepsy
    Radmanovic, B.
    Dejanovic, S. Djukic
    Ravanic, D.
    Mihajlovic, G.
    Pantovic, M.
    Janjic, V.
    Jovanovic, M.
    Radmanovic, O.
    Ilic, M.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 154 - 154
  • [20] Desvenlafaxine in the treatment of major depressive disorder
    Pae, Chi-Un
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (18) : 2923 - 2928